BioAtla (BCAB) has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share ...

BioAtla ( (BCAB)) has issued an announcement. On February 6, 2026, BioAtla, Inc. disclosed that it had received a Nasdaq determination to suspend trading of its common stock, citing the company’s ...

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

BioAtla, Inc. reported promising results for its treatment, Mecbotamab Vedotin (Mec-V), in patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS). At the ...

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval Company continues preparations for enabling ...

an improvement over the prior year’s $(0.44) (GAAP, Q2 2024). Operating expenses (GAAP) declined year over year, but cash reserves dropped sharply to $18.2 million by June 30, 2025. Advancement in ...

SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...